How Will the Biosimilar Market Change in 2018?



 
“Right now, I think we’re at 7 that have been approved by the FDA, with a couple more in the pipeline. I think, as of 2015, I believe IMS Health came out with something where there were 41 of these in development. So I know that there’s probably more coming on, and I think more will come on once we get some clarity from the FDA about what direction they’re going to do as far as regulating biosimilars, but I don’t think this a trend that’s going away anytime soon. At the end, we all want to lower prices, patients need to be taken care of by specialty pharmacies, and they realize that, and I know patients have become a lot more savvy about what’s out there. So, I think everybody’s really just trying to figure out how are biosimilars going to effect the market, and how much are they going to lower the price?”

 

Most Popular

Related Articles

Clinical trial demonstrates adoptive T-cell therapy may be successful in treating progressive multifocal leukoencephalopathy.
Top news of the day from across the health care landscape.
Top news of the day from across the health care landscape.
Company Profile >
Contributors >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Advertise
Careers
Contact Us
Terms & Conditions
Privacy
MJH Associates >
Pharmacy Times
OTCGuide
American Journal of Managed Care
Cure
MD Magazine
ONCLive
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.
 

$vacMongoViewPlus$